Artículo
Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice
Autor/es | Valdés Delgado, Teresa
Guerra Veloz, María Fernanda Castro Laria, Luisa Maldonado Pérez, Belén Perea Amarillo, Raúl Merino Bohórquez, Vicente Sáez, Antonia Caunedo Álvarez, Ángel Argüelles Arias, Federico |
Departamento | Universidad de Sevilla. Departamento de Farmacología Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2020 |
Fecha de depósito | 2024-05-09 |
Publicado en |
|
Resumen | Introduction: between 30 % and 40 % of patients treated
with infliximab lose response during maintenance. Ther apeutic drug monitoring could be used to optimize man agement in these situations. However, infliximab serum ... Introduction: between 30 % and 40 % of patients treated with infliximab lose response during maintenance. Ther apeutic drug monitoring could be used to optimize man agement in these situations. However, infliximab serum levels are not well defined. The aim of this study was to determine the cut-off range of infliximab serum levels in Crohn’s disease patients in remission in the clinical practice. Methods: an observational retrospective study was per formed from 2016 to 2017. Patients were included with established Crohn’s disease, who had been on a mainte nance dose schedule of infliximab. Infliximab levels and antibodies to infliximab were measured at least twice in all patients, after induction and after six months of treat ment. Clinical remission was defined as ≤ 4 using the Har vey-Bradshaw index. Cluster analysis was used to analyze the results. Results: one hundred and five Crohn’s disease patients were included in the study; 57.1 % were male with a mean age of 39 years (SD ± 12.9). The median (range) time of the disease was eleven years (7-15) and the median (range) time of follow-up was 32 months (22-38). Patients who achieved remission had infliximab serum levels between 4.26-8.26 ug/ml versus 0.06-1.43 ug/ml in patients who did not achieve remission after induction. Infliximab serum levels were 2.84-7.75 ug/ml and 0.05-2.69 ug/ml in patients who achieved remission versus those who did not achieve remission after six months of treatment. Overall, 4.26-8.26 ug/ml was found to be the best cut-off range for remission. Conclusions: in our clinical practice, serum levels of inflix imab in Crohn’s disease patients should be higher than 4 ug/ml to achieve clinical remission. |
Cita | Valdés Delgado, T., Guerra Veloz, M.F., Castro Laria, L., Maldonado Pérez, B., Perea Amarillo, R., Merino Bohórquez, V.,...,Argüelles Arias, F. (2020). Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice. Revista Española de Enfermedades Digestivas, 112 (10), 756-761. https://doi.org/10.17235/reed.2020.6539/2019. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Cut off ranges of infliximab.pdf | 694.0Kb | [PDF] | Ver/ | |